全文获取类型
收费全文 | 22875篇 |
免费 | 1643篇 |
国内免费 | 264篇 |
专业分类
耳鼻咽喉 | 82篇 |
儿科学 | 711篇 |
妇产科学 | 368篇 |
基础医学 | 4286篇 |
口腔科学 | 116篇 |
临床医学 | 2405篇 |
内科学 | 6793篇 |
皮肤病学 | 302篇 |
神经病学 | 492篇 |
特种医学 | 236篇 |
外国民族医学 | 1篇 |
外科学 | 1415篇 |
综合类 | 1038篇 |
一般理论 | 1篇 |
预防医学 | 4596篇 |
眼科学 | 128篇 |
药学 | 1107篇 |
3篇 | |
中国医学 | 76篇 |
肿瘤学 | 626篇 |
出版年
2024年 | 21篇 |
2023年 | 1257篇 |
2022年 | 1214篇 |
2021年 | 1500篇 |
2020年 | 1911篇 |
2019年 | 1125篇 |
2018年 | 1082篇 |
2017年 | 1083篇 |
2016年 | 1060篇 |
2015年 | 1223篇 |
2014年 | 1706篇 |
2013年 | 1368篇 |
2012年 | 1053篇 |
2011年 | 1009篇 |
2010年 | 1146篇 |
2009年 | 1004篇 |
2008年 | 582篇 |
2007年 | 591篇 |
2006年 | 526篇 |
2005年 | 462篇 |
2004年 | 373篇 |
2003年 | 368篇 |
2002年 | 355篇 |
2001年 | 341篇 |
2000年 | 306篇 |
1999年 | 303篇 |
1998年 | 229篇 |
1997年 | 155篇 |
1996年 | 184篇 |
1995年 | 133篇 |
1994年 | 102篇 |
1993年 | 76篇 |
1992年 | 86篇 |
1991年 | 81篇 |
1990年 | 77篇 |
1989年 | 52篇 |
1988年 | 85篇 |
1987年 | 75篇 |
1986年 | 55篇 |
1985年 | 52篇 |
1984年 | 40篇 |
1983年 | 24篇 |
1982年 | 36篇 |
1981年 | 25篇 |
1980年 | 23篇 |
1979年 | 33篇 |
1978年 | 30篇 |
1977年 | 29篇 |
1976年 | 30篇 |
1975年 | 23篇 |
排序方式: 共有10000条查询结果,搜索用时 531 毫秒
61.
62.
63.
65.
《Vaccine》2016,34(46):5677-5688
Mycobacterium tuberculosis (Mtb), the bacterial cause of tuberculosis, is a leading infectious agent worldwide. The development of a new vaccine against Mtb is essential to control global spread of tuberculosis, since the current vaccine BCG is not very effective and antibiotic resistance is a serious, burgeoning problem. ESAT-6 is a secreted protein of Mtb, which is absent in BCG but has been implicated in inducing protective immunity against Mtb. Peptide based subunit vaccines are attractive due to their safety and high specificity in eliciting immune responses, but small synthetic peptides are usually not very immunogenic. We have designed a novel subunit vaccine for Mtb by using simple lipid (palmitic acid) modified derivatives of peptides from ESAT-6 protein corresponding to dominant human T cell epitopes and examined their ability to stimulate protective immunity against Mtb by intranasal and subcutaneous immunization in mice. We also investigated how individual TLR agonists as adjuvants (PolyI:C, MPL and GDQ) contribute to enhancing the induced immune responses and resulting protective efficacy of our vaccine. We observed that single C-terminal palmitoyl-lysine modified lipopeptides derived from ESAT-6 induce significant cellular immune responses on their own upon mucosal and subcutaneous immunizations. Intriguingly, a combination of immunogenic lipopeptides of ESAT-6 antigen exhibited local (pulmonary) and systemic immune responses along with efficient protective efficacy when administered intranasally or subcutaneously. Surprisingly, combination of ESAT-6 derived lipopeptides with a TLR-4 agonist (MPL) enhanced protection, whereas TLR-3 (Poly I:C) and TLR-7/8 agonists (gardiquimod, GDQ) led to reduced protection associated with specific local and systemic immune modulation. Our studies demonstrate the potential of ESAT-6 derived lipopeptides as a promising vaccine candidate against Mtb, and emphasize that selection of adjuvant is critical for the success of vaccines. These findings demonstrate the promise of synthetic lipopeptides as the basis of a subunit vaccine for TB. 相似文献
66.
67.
《Vaccine》2020,38(51):8185-8193
BackgroundWhile administration of the measles-mumps-rubella (MMR-II®) vaccine has been effective at preventing rubella infection in the United States, the durability of humoral immunity to the rubella component of MMR vaccine has not been widely studied among older adolescents and adults.MethodsIn this longitudinal study, we sought to assess the durability of rubella virus (RV)-specific humoral immunity in a healthy population (n = 98) of adolescents and young adults at two timepoints: ~7 and ~17 years after two doses of MMR-II® vaccination. Levels of circulating antibodies specific to RV were measured by ELISA and an immune-colorimetric neutralization assay. RV-specific memory B cell responses were also measured by ELISpot.ResultsRubella-specific IgG antibody titers, neutralizing antibody titers, and memory B cell responses declined with increasing time since vaccination; however, these decreases were relatively moderate. Memory B cell responses exhibited a greater decline in men compared to women.ConclusionsCollectively, rubella-specific humoral immunity declines following vaccination, although subjects’ antibody titers remain well above the currently recognized threshold for protective immunity. Clinical correlates of protection based on neutralizing antibody titer and memory B cell ELISpot response should be defined. 相似文献
68.
69.
70.
《Joint, bone, spine : revue du rhumatisme》2019,86(3):335-341
ObjectiveRetinol-binding protein 4 (RBP4), systemic inflammation and insulin resistance (IR) are linked, yet the determinants of RBP4 and its impact on IR in rheumatoid arthritis (RA) are incompletely understood. The aim of this study was to explore the prevalence of IR in RA and investigate whether the serum levels of RBP4 were associated with IR in patients with RA.MethodsIn this study, 403 individuals with newly diagnosed and untreated RA were consecutively recruited. We calculated the Disease Activity Score assessed using 28-joint counts for swelling and tenderness (DAS28). Levels of serum RBP4, interleukin-6 (IL-6) and tumor necrosis factor (TNF) α were tested. IR was defined as Homeostasis model assessment for insulin resistance (HOMA-IR) index greater than or equal 2.40.ResultsIn those 403 patients, 68 (16.9%) were male and the median age was 43 years (IQR: 36–52). There was an evidently positive correlation between increased serum levels of RBP4 and increasing severity of RA (DAS28) (r = 0.403, P < 0.001). Furthermore, a modest positive correlation between levels of serum RBP4 and HOMA-IR score (r = 0.251; P < 0.0001) was found. Eighty-five patients (21.1%) in patients with RA were defined as IR (HOMA-IR ≥ 2.40), which was significantly higher than in normal cases (4.7%). In the patients with IR, serum levels of RBP4 were higher when compared with those in patients free-IR P < 0.001. The IR distribution across the quartiles of RBP4 ranged between 5.0% (first quartile) to 39.0% (fourth quartile), P for trend < 0.001. For each 1unit increase of RBP4, the unadjusted and adjusted risk of IR increased by 8% (OR: 1.08; 95% CI: 1.05–1.11, P < 0.001) and 5% (1.05; 1.02–1.09, P = 0.001), respectively. When RBP4 was added to the model containing established significant risk factors, AUROC (standard error) was increased from 0.768 (0.025) to 0.807(0.021). A significant difference in the AUC between the established risk factors alone and the addition of RBP4 was observed (difference, 0.039[0.004]; P = 0.02).ConclusionElevated serum levels of RBP4 were associated with increased risk of IR and might be useful in identifying RA at risk for IR and/or impaired glucose tolerance for early prevention strategies, especially in obese and women patients 相似文献